Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of the Hippo Signaling Pathway in Human Gastric Cancer

  • Zhou, Guang-Xi (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Li, Xiao-Yu (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhang, Qi (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhao, Kun (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhang, Cui-Ping (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Xue, Chang-Hu (College of Food Science and Engineering, Ocean University of China) ;
  • Yang, Kun (The Core Laboratory, The Affiliated Hospital of Qingdao University Medical College) ;
  • Tian, Zi-Bin (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College)
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aim: The Hippo signaling pathway is a newly discovered and conserved signaling cascade, which regulates organ size control by governing cell proliferation and apoptosis. This study aimed to investigate its effects in human gastric cancer. Methods: Tumor tissues (n=60), adjacent non-tumor tissues (n=60) and normal tissues (n=60) were obtained from the same patients with primary gastric cancer (GC). In addition, 70 samples of chronic atrophic gastritis (CAG) tissues were obtained from patients with intestinal metaplasia (IM) by endoscopic biopsy. Hippo signaling molecules, including Mst1, Lats1, YAP1, TAZ, TEAD1, Oct4 and CDX2, were determined by quantitative polymerase chain reaction (qPCR). Protein expression of Mst1, Lats1, YAP1, TEAD1 and CDX2 was assessed by immunohistochemistry and Western blotting. Results: Mst1, Lats1 and Oct4 mRNA expression showed an increasing tendency from GC tissues to normal gastric tissues, while the mRNA expression of YAP1, TAZ and TEAD1 was up-regulated (all P<0.01). Mst1 and Lats1 protein expression presented a similar trend with their mRNA expression. In addition, YAP1 and TEAD1 protein expression in GC was significantly higher than in the other groups (all P<0.01). CDX2 mRNA and protein expression in the CAG group were higher than in the other groups (all P<0.01). In GC, mRNA expression of Mst1, Lats1, Oct4, YAP1, TAZ, TEAD1 and CDX2 had a close correlation with lymphatic metastasis and tumor TNM stage (all P<0.01). Furthermore, protein expression of Mst1, Lats1, YAP1, TAZ, TEAD1 and CDX2 had a close correlation between each other (P<0.05). Conclusion: The Hippo signaling pathway is involved in the development, progression and metastasis of human gastric cancer. Therefore, manipulation of Hippo signaling molecules may be a potential therapeutic strategy for gastric cancer.

Keywords

References

  1. Barros R, da Costa LT, Pinto-de-Sousa J, et al (2011). CDX2 auto-regulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype. Gut, 60, 290-8. https://doi.org/10.1136/gut.2010.222323
  2. Chu J, Qin R, Wang N, et al (2011). Expression and significance of CDX2 and elaudin-3 in gastric carcinoma and paracancer tissue. J Clin Exp Pathol, 27, 1280-5.
  3. Freund JN, Domon-Dell C, Kedinger M, Duluc I (1998). The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol, 76, 957-69 https://doi.org/10.1139/bcb-76-6-957
  4. Harvey KF, Pfleger CM, Hariharan IK (2003). The Drosophila Mst Ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell, 114, 457-67. https://doi.org/10.1016/S0092-8674(03)00557-9
  5. Kang JM, Lee BH, Kim N, et al (2011). CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci, 26, 647-53. https://doi.org/10.3346/jkms.2011.26.5.647
  6. Liu X, Zhang X, Zhan Q, et al (2012). CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol Ther, 13, 1152-7. https://doi.org/10.4161/cbt.21344
  7. Matsuoka J, Yashiro M, Sakurai K, et al (2012). Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res, 174, 130-5. https://doi.org/10.1016/j.jss.2010.11.903
  8. Morrow DJ, Avissar NE, Toia L, et al (2009). Pathogenesis of Barrett's esophagus: Bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophagea cells. Surgery, 146, 714-22. https://doi.org/10.1016/j.surg.2009.06.050
  9. Nishioka N, Inoue K, Adachi K, et al (2009). The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell, 16, 398-410. https://doi.org/10.1016/j.devcel.2009.02.003
  10. Pan D (2010). The hippo signaling pathway in development and cancer. Dev Cell, 19, 491-505. https://doi.org/10.1016/j.devcel.2010.09.011
  11. Tajima Y, Yamazaki K, Makino R, et al (2006). Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic Background. Clin Cancer Res, 12, 6469-79. https://doi.org/10.1158/1078-0432.CCR-06-1339
  12. Trosko JE (2006). From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann N Y Acad Sci, 1089, 36-58. https://doi.org/10.1196/annals.1386.018
  13. Visser-Grieve S, Zhou Z, She YM, et al (2011). LATS1 Tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization. Cell Res, 21, 1513-6. https://doi.org/10.1038/cr.2011.122
  14. Wei W, Zhang C, Zhang Q, et al (2012). Expression of Hippo signaling molecules in gastric carcinogenesis. World Chin J Digestol, 20, 3027-32. https://doi.org/10.11569/wcjd.v20.i31.3027
  15. Wen J, Park JY, Park KH, et al (2010). Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas, 39, 622-6. https://doi.org/10.1097/MPA.0b013e3181c75f5e
  16. Xu Z, Zhu J, Zhang Q, et al (2011). A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology, 58, 1611-7.
  17. Yang L (2006). Incidence and mortality of gastric cancer in China. World J Gastroenterol, 12, 17-20. https://doi.org/10.3748/wjg.v12.i1.17
  18. Zeng Q, Hong W (2008). The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell, 13, 188-92. https://doi.org/10.1016/j.ccr.2008.02.011
  19. Zhao B, Lei QY, Guan KL (2008). The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol, 20, 638 - 46. https://doi.org/10.1016/j.ceb.2008.10.001
  20. Zhao B, Wei X, Li W, et al (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev, 21, 2747-61. https://doi.org/10.1101/gad.1602907
  21. Zheng T, Wang J, Jiang H, et al (2011). Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Letters, 302, 91-9. https://doi.org/10.1016/j.canlet.2010.12.008

Cited by

  1. Comparative Analysis of Oct4 in Different Histological Subtypes of Esophageal Squamous Cell Carcinomas in Different Clinical Conditions vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3519
  2. Overexpression of YAP1 is Correlated with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma vol.20, pp.4, 2014, https://doi.org/10.1007/s12253-014-9757-y
  3. Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer vol.35, pp.7, 2014, https://doi.org/10.1007/s13277-014-1826-z
  4. Methylation-associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma vol.45, pp.6, 2014, https://doi.org/10.3892/ijo.2014.2687
  5. Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein vol.36, pp.10, 2015, https://doi.org/10.1007/s13277-015-3539-3
  6. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1 vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3364-8
  7. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers vol.22, pp.3, 2016, https://doi.org/10.3748/wjg.v22.i3.1279
  8. Emerging role of Hippo signalling pathway in bladder cancer vol.22, pp.1, 2018, https://doi.org/10.1111/jcmm.13293
  9. TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells vol.51, pp.1, 2017, https://doi.org/10.3892/ijo.2017.3998
  10. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-11094-3
  11. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma pp.1532-2807, 2018, https://doi.org/10.1007/s12253-017-0225-3
  12. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis vol.17, pp.1, 2016, https://doi.org/10.3390/ijms17010138
  13. miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype vol.14, pp.4, 2017, https://doi.org/10.3892/ol.2017.6746
  14. Inhibitory effect and mechanism of exogenous mammalian sterile 20-like kinase 1 on the growth of human colorectal cancer vol.13, pp.4, 2017, https://doi.org/10.3892/ol.2017.5786
  15. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors vol.10, pp.3, 2018, https://doi.org/10.3390/cancers10030081
  16. Roles of the MST1-JNK signaling pathway in apoptosis of colorectal cancer cells induced by Taurine vol.13, pp.1, 2018, https://doi.org/10.1080/19932820.2018.1500346
  17. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts vol.51, pp.3, 2018, https://doi.org/10.5483/BMBRep.2018.51.3.018
  18. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma vol.10, pp.2, 2019, https://doi.org/10.1038/s41419-018-1281-7